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exacerbations, and reduce risk of long-term lung damage. 3 Yet while morbidity and mortality due to asthma are preventable, nearly 62% of adults with asthma remain uncontrolled, and implementation of potentially effective new interventions within real-world contexts has been limited. 4 There is no doubt that careful assessment, close follow-up, medication reminders, and self-management training all improve adherence and outcomes. 4 However, these approaches require personnel and time resources that may not exist within over-burdened healthcare systems. With the growing shortage of primary care providers (PCP) and the increasing complexity of clinical care, it is unlikely that PCPs can carve out additional time to focus on asthma management. 5 For this reason, interventions that can function effectively within existing systems' constraints and improve patient outcomes without increasing provider burden are urgently needed.
There is growing evidence that use of e-health technology (e.g. smartphones, electronic medical record, and computer decision-support software "CDSS") can address common asthma management issues. 6, 7 However, most technology-based interventions do not integrate with the electronic medical record (EMR), and are thus not currently clinically sustainable. While researchers may be optimistic about the ability to integrate ex post facto, few tech-based interventions cross the research to practice divide, typically due to unforeseen systems implementation issues or incompatibility with existing clinical workflow.
TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)
Thus, in designing a new technology-based intervention for asthma management, we adopted a contextually grounded intervention development approach that allowed for consideration of implementation issues during the development process 8 . Specifically, we sought to develop a smartphone-based telemedicine program that could address common asthma management problems (e.g. patient non-adherence, [9] [10] [11] inaccurate symptom reporting, 12, 13 poor self-management, 14, 15 access to care, [16] [17] [18] and provider nonadherence to asthma guidelines [19] [20] [21] and integrate with the EMR and existing clinical practice. The goal in developing the intervention was to increase the accuracy, effectiveness, and convenience of care for patients, while avoiding increased clinician burden and promoting adherence to guidelines. [22] [23] [24] [25] [26] In this manuscript, we describe the process of contextually grounded intervention development, the resulting technology, and proof of concept testing in a small, real-world sample of adult patients in a large urban medical center. We hypothesized that the intervention would show preliminary evidence of feasibility and acceptability and potential to improve asthma outcomes in younger adults with asthma.

Methods
Intervention Development
As shown in Table 1 , we navigated an extensive two-year planning and development process aligning with May's implementation theory, 27 including identifying problems and solutions, target environments, system capabilities, key stakeholders, practice policies, and credentialing processes. Development required establishing key relationships; assembling a representative team, creating and testing the technology, obtaining approval to launch, and proofof-concept testing with patients in the clinical setting.
Technology Enabled Asthma Management System (TEAMS) is a fully integrated EMR-
based intervention designed for use in primary care. Based on the process described above, three technological components were selected to augment routine asthma care: (a) remote smartphone symptom monitoring, (b) synchronous smartphone telemedicine follow-up and self-management training with a nurse, and (c) computer-guided EMR assessments using built-in clinical decisionsupport software (CDSS). Patients recorded home-entered symptoms using their smartphones and a patient portal app (Mychart; Epic Systems Corporation, Wisconsin USA), which uploaded symptom data directly to the Epic EMR. One nurse (JRM) conducted telemedicine visits using Zoom's HIPAA-compliant secure video-conferencing platform (Zoom Inc. California USA).
The nurse reviewed home-entered symptoms and entered a detailed asthma assessment into the TEAMS CDSS flowsheet (see Figure 1) , which is a complex clinical documentation and decision-making tool embedded in the EMR. Guideline-based algorithms in the CDSS tool instantaneously calculated asthma severity, control, and provided a comparison of recommended versus prescribed step-wise therapy. The CDSS tool was designed to improve assessment accuracy, guide step-wise medication management, 4 inform providers, and help patients achieve better asthma control. Results of the analyses were shared with the participant and evidencebased self-management training was provided using the free online resource Let's Talk About
Asthma! e-series for smartphone developed in our prior work. 28, 29 A detailed progress note autogenerated by the CDSS tool (see Figure E1 , online supplement) was filed in the EMR for each telemedicine visit. Per protocol, an EMR InBasket message with a visit summary was sent to the PCP team if the patient had uncontrolled asthma and needed medication adjustments or office follow-up, with a back-up phone call for urgent issues. Patients with confounding comorbidities (e.g. heart failure COPD, Cystic fibrosis) and pregnant patients were excluded. Patients with psychiatric diagnoses were not excluded. Ten patients, randomly selected from clinic rosters, were screened; all had smartphones. One was ineligible on the basis of heart failure and two who were eligible could not be re-contacted after screening.
The remaining seven consented and completed the beta-test (3-month duration).
Intervention delivery
Written informed consent and all study procedures were performed by a trained non- once a month. There was no minimum requirement for participation in self-monitoring or telemedicine visits and patients participated in each activity as often as they were motivated to.
Intervention dose for each participant was tracked and correlated with outcomes.
Outcome Measures
Feasibility was measured by: (a) frequency of participation in symptom monitoring, (b)
number of visits needed to achieve/maintain asthma control, (c) duration of visits, and (d) no
show and reschedule rates. Similar to clinical practice, length of visit was driven by the time it took to complete the asthma assessment, teach participants specific self-management skills, and relay follow up documentation to PCP/clinic. Thresholds for minimum or maximum intervention dose were not predefined, as the goal was not to deliver a standard intervention dose, but to assess dose needed to achieve good control or dose tolerated (e.g. frequency of voluntary participation), and relationship between intervention dose, asthma control, and quality of life.
Efficacy. Primary outcomes (asthma control, quality of life, and FEV1 percent predicted)
were collected at baseline and end of study. Asthma control and quality of life were measured using the Asthma Control Questionnaire (ACQ) 31 and Asthma Quality of Life Questionnaire (AQLQ), respectively.
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ACQ. The ACQ is a well-established 7-item questionnaire with a score range of 0-6 (lower scores represent better control). A score of ≦0.75 has a positive predictive value of 0.85 for controlled asthma, and a score of ≧ 1.5 has a positive predictive value of 0.88 for uncontrolled asthma. 31 Minimum important difference is a change score of 0.5.
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AQLQ. The AQLQ measures physical and emotional impact of disease with high testretest reliability (>0.90). 32 Averaged total scale and subscale scores range from 1-7, with higher scores representing better quality of life. Minimum important difference is 0.5 per domain and overall quality of life.
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FEV1 was measured using Microlife digital PFMs. 30 FEV1 percent predicted was calculated using NHANES III criteria. 35, 36 Number of prescriptions written by providers for asthma medications were obtained through EMR review for the year pre and post intervention.
Actual refills by patients could not be accurately determined due to external pharmacies data storage procedures.
Acceptability was assessed at the end of the study through 1:1 interview and the Usability
Satisfaction and Ease of Use Questionnaire (USE-Q). The USE-Q 37 is a validated 21-item
instrument with a 7-point Likert scale format (1=strongly disagree to 7=strongly agree). Higher scores represent more positive perceptions, with 7 being the most positive possible score and 1 representing the most negative possible score. Minimum acceptability thresholds were a score ≥5=somewhat agree on at least 70% of USE-Q items. Exit interviews were conducted to qualitatively explore acceptability.
Demographics were collected via survey and the EMR.
Data analysis
Descriptive statistics were computed for demographics, feasibility, and USE-Q data.
Paired t-tests were used to compare baseline and end of study scores for ACQ, AQLQ, and FEV1 percent predicted, and effect sizes (Cohen's d) were calculated. Unadjusted bivariate correlation was used to explore associations between asthma control and quality of life (ACQ, AQLQ) and
intervention dose (frequency of self-monitoring and telemedicine visits). Audio-recorded interviews were transcribed and qualitative content analysis techniques 38 were used to explore participants' perceptions of the program.
Results
Baseline asthma and demographic data are presented in Table 2 .
Feasibility. Of 42 scheduled telemedicine visits, 7 were no-shows (16%; involving 4/7 patients), 7 rescheduled (16%; involving 4/7 patients), and 28 were conducted as expected Participants were asked to set a daily reminder on their smartphone; no external reminders were provided for self-monitoring. Average telemedicine visit duration was 29 minutes (range 20-45 minutes), and the majority of visits (17/28; 61%) were delivered after 5pm or on weekends to accommodate participants' work schedules.
Efficacy. At baseline, all participants had uncontrolled asthma. At 3-months, 6/7 participants had marked reduction in symptoms with 5/7 classifying as well-controlled 39 . Effect sizes were large for improvements in control, quality of life, and FEV1 percent predicted (d=0.96 to 1.16). Table 3 shows pre-post scores for asthma outcomes with effect sizes and confidence intervals. On average, asthma control improved 1.55 points-more than 3 times the clinical MID. Significant improvements were seen in morning symptoms, night time wakening, activity limitations and shortness of breath, with greatest effects on reductions in wheezing (d=1.48).
Quality of life improved an average of 1.91 points, nearly 4 times the minimum important TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS) difference (MID). Improvements were evenly distributed across all domains (symptoms, activity limitations, emotional functioning, and environmental stimuli. There was also an average increase of approximately 15% in FEV1 percent predicted. Table 4 shows individual peak flow graphs (extracted from the EMR) with a noticeable upward trend in PEF for most participants. Graphs for the first two participants showed downward or neutral trends. Association between number of days participants performed home self-monitoring, length of visit, and improvement in asthma control was moderate (r= 0.67 and p=0.10).
An average of 2 (range 1-4; SD 1.29) InBasket messages per participant were sent by the TEAMS nurse to the participants' PCP (n=4) over 3 months, to coordinate follow-up care and medication adjustments, with 100% PCP response. As seen in Table 3 , there were significant and clinically meaningful increases in use of preventive health services and written prescriptions for controller medications, and a corresponding decrease in prescriptions for oral corticosteroids in the year following intervention.
Acceptability. As shown in Table 5 , acceptability and satisfaction was high (93.9%). At exit interviews, six of seven participants reported that the intervention "changed my life" and enabled them to take control of their asthma for the first time. Qualitative data on the perceived impact of the intervention are presented in Table 4 .
TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)
Discussion
Data from this proof-of-concept study suggest that use of an integrated smartphone and EMR/practice-based intervention might be an effective means to supplement primary asthma care and improve outcomes. The underlying importance of this approach lies in the ability to reduce barriers to accessing primary care. 18 Telemedicine is inherently more flexible than office care, and does not require that patients travel to a given location. Extending telemedicine into patients' homes via ubiquitously available smartphones could make communities the front-line for primary care. Because of ability to supersede geographic boundaries, smartphone technology could increase clinical reach, and may thus be the key to delivering care to underserved populations locally and globally.
Prior studies have demonstrated that use of remote monitoring, self-management training, telemedicine, smartphones, and CDSS tools, individually, can improve outcomes. [40] [41] [42] To our knowledge, however, this is the first intervention to combine these components into a single technological package that effectively integrates with real-world medical practice and the live EMR.
In contrast to studies that have sought to isolate and quantify the impact of individual factors, 43, 44 this study adopted a broad-spectrum approach with simultaneous intervention across multiple patient, provider and systems levels, as we theorized that the impact of a multifaceted program would likely be different from the impact of individual components in isolation 45, 46 .
The marked improvement in outcomes, as evidenced by large effect sizes on key outcomes (d=0.96 to 2.62), supports this holistic approach. On average, participants achieved a 15% increase in FEV1, crossing the critical clinical threshold of >80%. 39 Additionally, improvements in asthma control and quality of life that were 3-4 times the minimum important difference. 31, 34 Patients' perceptions of acceptability and feasibility were high, and while participants only recorded symptoms only 33% of the time on average, greater engagement was associated with improved asthma control. Lastly, the significant increase in written prescriptions for controller medications and in-office PCP follow up suggest that the intervention can promote provider adherence to guideline-based care, in addition to improving patient specific outcomes.
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From a systems standpoint, clinical feasibility and affordability has yet to be determined.
In this small sample, no-show and reschedule rates for telemedicine visits was only slightly better than office visit attendance rates (66%), with 68% of telemedicine visits conducted as expected 48 . Further research is needed to determine cost-effectiveness and institutional capability to run a program that operates heavily during evening and weekend hours.
Furthermore, given that participants required an average of 114 minutes of individualized asthma education with a nurse to achieve and maintain control, the TEAMS approach is likely to require greater upfront investment by insurers and the medical community to achieve long-term societal
gain. Yet, it is abundantly clear that current approaches to "feasible and affordable care" are not effective, as the majority of patients with asthma remain chronically uncontrolled. Thus, it may be necessary to stretch healthcare boundaries and explore ways to make effective care affordable, rather than perpetuating systems that are affordable but largely ineffective. In short, moving towards an aggressively proactive rather than reactive approaches to asthma management is essential to changing long-term health trajectories. 46 Limitations. This proof-of-concept study used a small sample. Patients were predominantly younger, minority, lower SES, lower health-literacy, with moderate/severe uncontrolled asthma, and the intervention was delivered by a single nurse. Further research in a larger and more representative population, with diverse interventionists is needed to replicate
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findings, evaluate who the intervention is most effective for, and determine if all intervention components are necessary to achieve similar outcomes.
Despite limitations, we believe these data are compelling, and the processes delineated herein will be useful to those seeking to develop and implement technology-based clinical interventions. Several important lessons were learned: First, the technology took nearly two years to conceptualize, build, and integrate into practice, which was longer than anticipated. The majority of this time was spent navigating systems level barriers, gaining access to EMR build/programming environments, and getting healthcare provider buy-in. It is well-known that many potentially effective interventions are never integrated into clinical practice or the EMR.
Our experience suggests that this may be partly due to failure to account for powerful real-world constraints. As seen throughout the development process (Table 1) , we found that wherever the intervention disrupted existing practice (even by small amounts), it was met with resistance.
Conversely, by avoiding workflow changes and carefully incorporating stakeholder feedback, we were able to minimize resistance and increase support for the intervention. It is also worth noting that even with using a contextually-grounded intervention development approach, where the intervention was crafted to the clinical context, there was still need for additional on-theground customization to account for unanticipated barriers (e.g. trouble engaging patients in office settings; preference of clinic providers to delegate use of the CDSS tool to nursing care).
Thus, the final intervention that was implemented was noticeably different than originally conceptualized. Use of focus groups, interviews, community engagement studios, and close collaboration with key stakeholders are important precursors to developing a clinically sustainable intervention. 27 Additionally, careful negotiation of institutional practices for new EMR build and IT and administrative support will be essential, as there are substantial barriers to new technology within the EMR due to potential for far-reaching negative systems impact.
Based on these experiences, we conclude that use of advanced EMR, CDSS, and smartphone technology has strong potential to improve asthma care, but premature intervention development without sufficient groundwork could be detrimental to long-term success. Capabilities: Symptoms can be monitored remotely with smartphones via patient portal to EMR interface • Guideline-based algorithms and decision support tools in EMR can minimize inaccuracies in clinical care • Home-based telemedicine can improve access to care Barriers: institutional cap on EMR build > 10 hours -requires formal review for priority and funding; research considered lower priority than clinical applications; limited funding available; initial plan to have clinic nurses do telemedicine visit was found to be non-viable due to patient need for evening and weekend visits, resulting in use of dedicated nurse interventionist Key stakeholders
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• Define potential impact of intervention (development and implementation) on patient, staff, and systems revenue or resources to identify stakeholders • Recognize and respect needs and perspectives of stakeholders who may impact intervention uptake (e.g. patient, community, support staff, nursing, provider, administrative, IT and data security, research, reporting, insurers)
Interviews and community engagement studios to engage: • Determine what certifications may be necessary to obtain approval or facilitate development of the intervention (e.g. specific build or reporting certifications) • Identify needed permissions (e.g. IRB, clinical administration, provider/staff approvals or "buy-in")
• (Urgent) Epic builder certification of researcher needed due to limited build resources; EMR build had to be performed by researcher, and administrative approval was needed at multiple levels to support this • (Delayed) Asthma educator certification necessary for eventual insurance billing Funding sources
• Identify immediate funding sources and potential for long-term sustainable funding 
